Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

80%

8 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

4(40.0%)

Phase 4

4(40.0%)

N/A

2(20.0%)

10Total

Phase 3(4)

Phase 4(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06184659Phase 4Recruiting

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

Role: lead

NCT03668236Phase 4Completed

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Role: collaborator

NCT04401514Not ApplicableCompleted

Does Rocking Charis Calm Delirious Patients in the Intensive Care Unit

Role: lead

NCT03392376Phase 4Unknown

Agents Intervening Against Delirium in Intensive Care Unit

Role: collaborator

NCT05195242Phase 3Completed

The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19

Role: collaborator

NCT04509973Phase 3Completed

Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia

Role: lead

NCT04348305Phase 3Completed

Hydrocortisone for COVID-19 and Severe Hypoxia

Role: lead

NCT01485315Phase 3Completed

Transfusion-requirements in Septic Shock Trial

Role: lead

NCT01020916Not ApplicableCompleted

Target Temperature Management After Cardiac Arrest

Role: collaborator

NCT00922714Phase 4Terminated

Scandinavian Intensive Care Unit (ICU) Glutamine Study

Role: lead

All 10 trials loaded